Drug Trial Radar · NCT04780217
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
42
Planned (sponsor's estimate)
Start
Aug 10, 2021
Primary completion
Mar 2025
Study completion Aug 2025
Sponsor
- Lead sponsor
- ImmVira Pharma Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors
Conditions
- Solid Tumor
- Hepatocellular Carcinoma
- Colorectal Cancer
- NSCLC
- Ovarian Cancer
- Endometrial Cancer
Interventions
T3011Biological
T3011 will be administered through IV drip or pumping.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of escalating doses of single agent IV T3011 Characterize DLTs and identify the MTD and/or the RP2D of single agent IV T3011Time frame: Up to 2 years from first dose of T3011
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Phoenix, Arizona
BRCR Medical Center Inc
Plantation, Florida
Prisma Health - Upstate
Greenville, South Carolina
Virginia Cancer Specialists
Greenville, South Carolina
Sarah Cannon Research Institute
Nashville, Tennessee
Mary Crowley Cancer Research
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.